It was in the s4me discussion. I think the more interesting question is why you put so much stock in a study you admit is exploratory, which you havent checked for validity.
Two studies that explore metabolic pathways in different ways. That doesn't mean they "failed to replicate". This happens all the time in science, especially EBV research. For example they failed to find EBV reactivation in long covid in one study, but then also found that it is a smoking gun in others. Aside that, what is your gripe with the Penn study?